Tempus AI, Inc. (NASDAQ: TEM), a leader in advancing precision medicine through AI technology, has announced that four of its abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain, from September 13-17, 2024.
Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus, commented, “ESMO provides an excellent platform to share our latest research and innovations with the global oncology community. We look forward to fostering collaboration and advancing our mission to improve patient outcomes. At Tempus, we are dedicated to transforming cancer care through AI and data, and this event offers a valuable opportunity to showcase our impactful approaches.”
Tempus will present its recent scientific and clinical research findings through one oral presentation and three poster presentations:
Oral Presentation (#CN13): Impact of AI Clinical Trial Program on Screening, Matching, and Enrollment of Patients Over 6 Months
- Date & Time: Monday, September 16, 2024; 11:05-11:15 a.m. CEST
- Location: Fira Barcelona Gran Via; Hall 7
- Overview: In collaboration with Cleveland Clinic, Tempus’ TIME initiative has improved large-scale patient screening and clinical trial matching, leading to enhanced patient enrollment and access, with an average of over one consent per day during a six-month period. The study recommends using AI for patient matching to optimize clinical trial success.
Poster Presentation (#113P): The Association of Changes in Circulating Tumor Fraction and Actionable Variant Allele Frequencies with Clinical Outcomes in a Diverse Cohort of Advanced Patients Treated with Tyrosine Kinase Inhibitors
- Date & Time: Sunday, September 15, 2024; 9:00 a.m.-5:00 p.m. CEST
- Location: Fira Barcelona Gran Via; Hall 6
- Overview: This study evaluates circulating tumor DNA (ctDNA) for monitoring treatment response in advanced solid tumor patients treated with tyrosine kinase inhibitors (TKIs). Using the Tempus xM ctDNA assay, patients were classified as molecular responders (MRs) or non-responders (nMRs) based on ctDNA tumor fraction (TF). MRs showed longer overall survival compared to nMRs. The study suggests that ctDNA TF monitoring may provide additional clinical insights beyond variant allele frequencies (VAF).
Poster Presentation (#79P): Comprehensive Genomic Profiling Provides Patients Access to Novel Matched Therapies in a Diverse Real-World Cohort of Advanced Lung Cancer Patients
- Date & Time: Sunday, September 15, 2024; 9:00 a.m.-5:00 p.m. CEST
- Location: Fira Barcelona Gran Via; Hall 6
- Overview: This study assessed adherence to guideline-recommended targeted therapies and the timing of treatment initiation in advanced non-small cell lung cancer (NSCLC) patients. It found that most oncologists used comprehensive genomic profiling (CGP) to identify and treat patients with variant-matched therapies, with adherence rates varying by variant. Patients who received CGP results before FDA approval of novel therapies still received matched treatment once these therapies were included in guidelines.
Poster Presentation (#580P): Impact of RAS and BRAFV600E Mutations on Tumor Immune Microenvironment and Associated Genomic Alterations in Patients with Microsatellite Instability (MSI) or DNA Mismatch Repair Deficient (dMMR) Colorectal Cancers
- Date & Time: Monday, September 16, 2024; 9:00 a.m.-5:00 p.m. CEST
- Location: Fira Barcelona Gran Via; Hall 6
- Overview: This study explored the impact of RAS and BRAF mutations on prognosis and treatment effects in MSI/dMMR colorectal cancers. Findings suggest that MSI/dMMR CRCs with RAS mutations are less immunogenic and have a lower tumor inflammatory profile compared to those with RAS wild-type or BRAF V600E mutations. Further analysis is needed to validate these results.
